Black Diamond Therapeutics, Inc. (BDTX) stock
BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$1.44−0.09 (-5.88%)
Close on Nov 17, 2026Market cap $82.73MP/E –Yield –
Black Diamond Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Black Diamond Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $28.13M, down 37.5% year over year. For fiscal 2025 it was $33.56M, down 34.6% from the year before. The highest annual figure on record is $96.83M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.56M | -34.6% |
| FY2024 | Dec 31, 2024 | $51.31M | -13.5% |
| FY2023 | Dec 31, 2023 | $59.35M | -7.9% |
| FY2022 | Dec 31, 2022 | $64.44M | -33.5% |
| FY2021 | Dec 31, 2021 | $96.83M | +100.9% |
| FY2020 | Dec 31, 2020 | $48.21M | +121.6% |
| FY2019 | Dec 31, 2019 | $21.75M | +213.0% |
| FY2018 | Dec 31, 2018 | $6.95M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $7.39M | -20.7% |
| Q1 FY2026 | Mar 31, 2026 | $7.00M | -33.3% |
| Q4 FY2025 | Dec 31, 2025 | $6.30M | -48.8% |
| Q3 FY2025 | Sep 30, 2025 | $7.44M | -42.4% |
| Q2 FY2025 | Jun 30, 2025 | $9.32M | -25.8% |
| Q1 FY2025 | Mar 31, 2025 | $10.51M | -22.4% |
| Q4 FY2024 | Dec 31, 2024 | $12.30M | -19.6% |
| Q3 FY2024 | Sep 30, 2024 | $12.91M | -20.1% |
| Q2 FY2024 | Jun 30, 2024 | $12.56M | -4.5% |
| Q1 FY2024 | Mar 31, 2024 | $13.55M | -8.2% |
| Q4 FY2023 | Dec 31, 2023 | $15.29M | +4.7% |
| Q3 FY2023 | Sep 30, 2023 | $16.15M | +1.9% |
| Q2 FY2023 | Jun 30, 2023 | $13.15M | -18.8% |
| Q1 FY2023 | Mar 31, 2023 | $14.75M | -17.1% |
| Q4 FY2022 | Dec 31, 2022 | $14.61M | -25.7% |
| Q3 FY2022 | Sep 30, 2022 | $15.85M | -42.6% |
| Q2 FY2022 | Jun 30, 2022 | $16.20M | -39.4% |
| Q1 FY2022 | Mar 31, 2022 | $17.79M | -22.1% |
| Q4 FY2021 | Dec 31, 2021 | $19.66M | +10.7% |
| Q3 FY2021 | Sep 30, 2021 | $27.63M | +113.7% |
| Q2 FY2021 | Jun 30, 2021 | $26.72M | +162.7% |
| Q1 FY2021 | Mar 31, 2021 | $22.82M | +210.3% |
| Q4 FY2020 | Dec 31, 2020 | $17.76M | +138.0% |
| Q3 FY2020 | Sep 30, 2020 | $12.93M | +129.5% |
| Q2 FY2020 | Jun 30, 2020 | $10.17M | +80.1% |
| Q1 FY2020 | Mar 31, 2020 | $7.35M | +144.1% |
| Q4 FY2019 | Dec 31, 2019 | $7.46M | – |
| Q3 FY2019 | Sep 30, 2019 | $5.63M | – |
| Q2 FY2019 | Jun 30, 2019 | $5.65M | – |
| Q1 FY2019 | Mar 31, 2019 | $3.01M | – |
See a number that looks wrong?